Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3

Status

Completed 3Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 69OTHER 59NIH 6NETWORK 6

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 5Gynecologic 1

Conditions

Breast Neoplasms 5Recurrent Uterine Corpus Carcinoma 1Neoplasm Metastasis 1

Interventions

Radiotherapy 87Cyclophosphamide 84Cisplatin 79Doxorubicin 66Vincristine 62Paclitaxel 55Etoposide 50Carboplatin 49Filgrastim 48Methotrexate 41Prednisone 40Cytarabine 37Granulocyte Colony-Stimulating Factor 35Radiotherapy, Intensity-Modulated 31Platinum 31Docetaxel 31Gemcitabine 30Leucovorin 28Dexamethasone 28Radiotherapy, Conformal 27Fluorouracil 27Cetuximab 26Taxes 24Rituximab 23Irinotecan 231,2-diaminocyclohexaneplatinum II citrate 23Radiation 21merphos 20Bevacizumab 19Temozolomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
NETWORK × Has results × Fulvestrant × Clear all
NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 2 Completed
180 enrolled 14 charts
Breast

Breast Neoplasms

NCT04650581 2026-04-13

FINER

Canadian Cancer Trials Group

Phase 3 Active not recruiting
250 enrolled 13 charts
Breast

Breast Neoplasms

NCT02536742 2024-02-26

PYTHIA

ETOP IBCSG Partners Foundation

Phase 2 Completed
124 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02137837 2021-01-28

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

SWOG Cancer Research Network

Phase 3 Terminated
37 enrolled 16 charts
Breast

Breast Neoplasms

NCT00075764 2021-01-13

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

SWOG Cancer Research Network

Phase 3 Completed
695 enrolled 15 charts
Breast

Breast Neoplasms

NCT00006903 2019-03-20

Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer

GOG Foundation

Phase 2 Unknown
67 enrolled 9 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡